Cytokinetics Inc (NAS:CYTK)
$ 59.23 -0.91 (-1.51%) Market Cap: 6.21 Bil Enterprise Value: 6.44 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 41/100

Cytokinetics Inc at Barclays Global Healthcare Conference Transcript

Mar 15, 2023 / 07:35PM GMT
Release Date Price: $37.27 (-1.30%)
Carter Lewis Gould
Barclays Bank PLC, Research Division - Senior Analyst

Good afternoon, and welcome to Day 2 of the Barclays Global Healthcare Conference. My name is Carter Gould, senior biopharma analyst here at Barclays. I am pleased to welcome Cytokinetics to the stage. Already had a very exciting start to the year, is just coming off ACC 10 days ago. Joining from the company CEO and President, Robert Blum. Robert, welcome.

Robert I. Blum
Cytokinetics, Incorporated - CEO, President & Director

Thanks very much.

Carter Lewis Gould
Barclays Bank PLC, Research Division - Senior Analyst

Do you want to make some opening comments and then we can get started or just jump into Q&A?

Robert I. Blum
Cytokinetics, Incorporated - CEO, President & Director

Very briefly. This year is a very important year for the company. We are in the midst of a pivot and redeployment and refocusing as is oriented towards aficamten, which is our next-in-class cardiac myosin

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot